This is an aggregated industry headline. Read the full story at BioPharma Dive →
Jasper gets a lifeline in merger with immune drugmaker Kira
The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
By BioPharma Dive
· Jul 17, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w…
The WeekFierceBiotech ↗
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Thera…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…